趙世佳

[摘要] 目的 觀察老年慢性心力衰竭患者應(yīng)用沙庫(kù)巴曲纈沙坦鈉聯(lián)合β-受體阻滯劑治療的臨床效果。 方法 選取2015年10月至2019年10月我院收治的老年慢性心力衰竭患者76例，隨機(jī)分為對(duì)照組和試驗(yàn)組，每組各38例。對(duì)照組給予β-受體阻滯劑治療，試驗(yàn)組給予沙庫(kù)巴曲纈沙坦鈉聯(lián)合β-受體阻滯劑治療。比較兩組患者心功能相關(guān)指標(biāo)，具體包括LVESD、LVEDD、LVEF及BNP，臨床試驗(yàn)室指標(biāo)（Gal-3、sST2、sICAM-1、GDF-15）及治療的安全性、有效性。 結(jié)果 治療后試驗(yàn)組患者LVESD、LVEDD及BNP顯著低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）;試驗(yàn)組患者的LVEF顯著高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）;試驗(yàn)組患者的Gal-3、sST2、sICAM-1及GDF-15顯著低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）;試驗(yàn)組治療總有效率顯著高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）;兩組治療后不良反應(yīng)總發(fā)生率比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）。 結(jié)論 在老年慢性心力衰竭患者治療中應(yīng)用沙庫(kù)巴曲纈沙坦鈉聯(lián)合β-受體阻滯劑治療效果顯著，且整體安全性高。

[關(guān)鍵詞] 沙庫(kù)巴曲纈沙坦鈉;β-受體阻滯劑;老年慢性心力衰竭;心功能不全

[中圖分類號(hào)] R541? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] B? ? ? ? ? [文章編號(hào)] 1673-9701（2021）24-0050-04

Clinical efficacy on the treatment of elderly patients with chronic heart failure with sacubitril valsartan sodium combined with β-blockers

ZHAO Shijia

Department of Cardiovascular Internal Medicine， Huludao Center Hospital in Liaoning Province， Huludao? ?125000， China

[Abstract] Objective To analyze the observation on the clinical efficacy on the treatment of elderly patients with chronic heart failure with sacubitril valsartan sodium combined with β-blockers. Methods A total of 76 elderly patients with chronic heart failure admitted to our hospital from October 2015 to October 2019 were selected and randomly divided into the control group （n=38） and the experimental group （n=38）. The control group was treated with β-blockers， while the experimental group was treated with sacubitril valsartan sodium combined with β-blockers. The related indexes of cardiac function between patients in the two groups were compared， including the values of LVESD， LVEDD， LVEF and BNP， clinical laboratory index of Gal-3， sST2， sICAM-1 and GDF-15， as well as the safety and efficacy of the treatment. Results The values of LVESD， LVEDD and BNP in the experimental group were significantly lower than those in the control group， with significant difference （P<0.05）. The LVEF of patients in the experimental group was significantly higher than that in the control group， with significant difference（P<0.05）. The values of Gal-3， sST2， sICAM-1 and GDF-15 of patients in the experimental group were significantly lower than those in the control group， with significant difference （P<0.05）. The total effective rate in the experimental group was significantly higher than that in the control group， with significant difference（P<0.05）， and there were no statistically significant differences in the total incidence of adverse reactions between the two groups after treatment （P>0.05）. Conclusion In the treatment of elderly patients with chronic heart failure， the application of sacubitril valsartan sodium combined with β-blockers has significant therapeutic efficacy and high overall safety.